We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device

By LabMedica International staff writers
Posted on 03 Dec 2025

Routine blood tests remain dependent on off-site laboratories, resulting in delays, higher costs, and logistical barriers in decentralized care settings. More...

Now, a new multimodal diagnostic solution delivers lab-quality results from a small blood sample in minutes, simplifying workflows and expanding access to timely testing.

Truvian Health (San Diego, CA, USA) has developed the TruVerus benchtop analyzer that is capable of running clinical chemistries, immunoassays, and hematology assays on a single platform. Until now, no single on-site platform could run clinical chemistry, immunoassays, and hematology in a single device. By uniting three major testing modalities in one device, TruVerus represents a significant shift toward decentralized diagnostics.

TruVerus integrates patented technologies and proprietary dry-reagent architecture to deliver comprehensive results from a fraction of the blood required by traditional testing. The compact, plug-and-play instrument provides automated, lab-accurate results within minutes and is designed to eliminate send-outs while reducing the complexity of routine diagnostics.

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for TruVerus. The system’s initial clearance includes a kidney health panel measuring creatinine, blood urea nitrogen (BUN), and eGFR. Each test run uses a disposable disc and a support pack that contains all necessary reagents for multimodal analysis. Additional assay panels have already been submitted for FDA review as part of the company’s staged-clearance strategy to build a full menu of routine blood tests on a single, automated benchtop platform.

“Truvian is poised to disrupt the diagnostics industry by creating a future where full lab testing is decentralized, improving access, and providing results in minutes, while using only a fraction of the blood needed for other routine blood testing,” said Michael J. Mina, MD, Ph.D., one of the leading diagnostics and industry experts and member of Truvian’s scientific advisory board. “This boldly empowers providers to deliver faster, more informed, and ultimately, more equitable care.”

Related Link
Truvian Health


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.